John Campbell completed his PhD in Pathology at Edinburgh in 1995, and has worked in the cellular therapy field for more than 30 years across the academic, biotechnology and healthcare sectors. He holds academic appointments at the Universities of Glasgow and Edinburgh and has published widely in the fields of cellular therapy and immunology. Whilst working in industry, he was heavily involved in development of reagents and equipment to drive the manufacture and characterization of cellular therapeutics, including design and launch of new flow cytometers. He has a special interest in the manufacture of therapeutic T cells and technological advances to make this more reliable and efficient. For the past 10 years John has been Director of Tissues, Cells and Advanced Therapeutics at the Scottish National Blood Transfusion Service (SNBTS) in Edinburgh and the national head of research for SNBTS. John is member of the BP/MHRA expert committee that published a recent white paper on the use of flow cytometry for characterization of cellular therapeutics, and is the scientific lead (chair) of the 2022 BP/MHRA expert committee on potency assays for NK and T cells. John is a co-founder of Resolution Therapeutics Ltd – a Scottish-based, world-leading macrophage therapy company. In late 2022, he will move to take up a CSO role in a newly-founded international cancer immunotherapy company, while continuing his academic cancer T cell therapy research.